Krasnodembskaya’s research group works with Mesenchymal Stem Cells (MSCs) with the  particular focus  on the MSC based   cell therapy for Acute Respiratory Distress Syndrome (ARDS). ARDS constitutes a  spectrum of severe acute respiratory failure and is leading cause of morbidity and mortality in critically ill patients with no available pharmacological treatment.

Our central goal is to understand how MSCs work in the context of the injury microenvironment, how MSCs modulate reparative capacities of the host cells and if we can enhance MSC therapeutic potential. More recently we became interested in therapeutic potential of MSC-derived extracellular vesicles as a potential cell-free therapy.